ANZ

Australia/New Zealand Heart Failure Collaborative Group trial. A trial assessing the effectiveness of carvedilol, a beta blocker, in managing systolic heart failure.
Conclusion Carvedilol patients had a 27% lower mortality, 30% reduction in hospitalisation, but the decrease was not statistically significant.

Mentioned in

accelerans
arteriosclerosis obliterans
arteritis obliterans
bronchiolitis fibrosa obliterans
bronchiolitis obliterans with organizing pneumonia
Culex restuans
dermatofibrosarcoma protuberans
elastosis perforans serpiginosa
endarteritis obliterans
endarteritis proliferans
Evans blue
exulcerans
Hamman's disease
obliterative bronchitis
Pantoea agglomerans
pericarditis obliterans
thromboangiitis obliterans

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.